Skip to main content
UniHealth

Doctor search

Andrew R Rezvani, MD

Hematopoietic Cell Transplantation and Cellular Therapy · Stanford

NPI 1609983485

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
17
3 carriers
Office
1
Since medical school
25 years
Temple University School of Medicine, 2001

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Rezvani’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence C128390 · Current

Licensed to practise in California · since 2014 · expires 2027-05-31 · Temple University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

State licence records

1 licence

  • Washington MD.MD.00043918Physician And Surgeon License · since 2004 · expires 2015-05-31
    ExpiredNo board action on this licenceCheck it with the state

We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

  • American Board of Internal Medicine - Medical Oncology

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$40,585

Medicare paid this office $40,585 for 64 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes27$23,129$105
Long return visit (40+ min)27$8,165$126
Long return visit (40+ min)17$5,354$167
Initial hospital care with moderate level of medical decision making at least 75 minutes13$1,854$143

Who their Medicare patients are

64 Original Medicare patients in 2024. Average age 69 · Women 48% · Also on Medicaid 34% · Health risk score 3.82. Sicker patients than 9 in 10 peers; the typical hematopoietic cell transplantation and cellular therapy clinician is at 2.85.

Conditions among them: High blood pressure 72% · Chronic kidney disease 38% · Depression 28% · Diabetes 23% · Atrial fibrillation 23% · Coronary heart disease 19% · Heart failure 19% · COPD 17% · Dementia 17%.

The office billed $153,233, Medicare allowed $52,297 and paid $40,585; for 349 services of 7 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
202464349693.82$153,233$40,585
202343189683.58$85,996$22,478
202266435673.00$194,677$47,065
202158247642.76$122,674$28,314
202057313684.21$150,014$31,847
201978292663.37$124,688$28,895
201869276643.66$111,917$27,533
201769279653.29$122,330$26,743
201671214663.42$108,331$20,604
201541167642.65$82,981$16,517
201467348633.15$141,889$34,135
201335255622.93$69,481$21,339

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 2 services

Original Medicare services billed in 2023
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes14$13,383$110
Long return visit (40+ min)26$5,759$131

2022: 4 services

Original Medicare services billed in 2022
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes29$23,825$93
Long return visit (40+ min)35$15,820$125
Initial hospital care with moderate level of medical decision making at least 75 minutes14$2,699$180
Hospital discharge day management, more than 30 minutes15$1,564$98

2021: 2 services

Original Medicare services billed in 2021
Long return visit (40+ min)30$12,890$126
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes21$9,830$94

2020: 5 services

Original Medicare services billed in 2020
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes26$16,054$96
Long return visit (40+ min)21$5,134$103
Initial hospital care with moderate level of medical decision making at least 75 minutes13$3,167$186
Return visit (30+ min)12$2,368$74
Hospital discharge day management, more than 30 minutes11$1,305$100

2019: 2 services

Original Medicare services billed in 2019
Long return visit (40+ min)41$11,608$96
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes27$10,659$94

2018: 3 services

Original Medicare services billed in 2018
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes23$12,077$94
Long return visit (40+ min)33$8,636$93
Hospital discharge day management, more than 30 minutes11$1,086$99

2017: 4 services

Original Medicare services billed in 2017
Long return visit (40+ min)32$11,873$94
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes23$9,441$93
New patient visit (45+ min)13$1,502$116
Hospital discharge day management, more than 30 minutes12$1,128$94

2016: 2 services

Original Medicare services billed in 2016
Long return visit (40+ min)44$12,247$93
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes20$4,352$93

2015: 1 service

Original Medicare services billed in 2015
Long return visit (40+ min)35$13,061$98

2014: 3 services

Original Medicare services billed in 2014
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes32$15,342$92
Long return visit (40+ min)35$12,602$98
Hospital discharge day management, more than 30 minutes14$1,352$97

2013: 2 services

Original Medicare services billed in 2013
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes19$13,813$84
Long return visit (40+ min)14$3,977$86

Medicaid work

$25,750 in 2024

Medicaid paid $25,750 for 167 billed services this clinician did in 2024, up to 19 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Long return visit (40+ min)167$25,750
Medicaid work by year
2024167119$25,750
202318116$1,377
202131112$2,290
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Long return visit (40+ min)18$1,377

2021

Largest Medicaid services in 2021
Long return visit (40+ min)31$2,290

Drugs they prescribed that Part D paid

$1,095,878

Pharmacies billed $1,095,878 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

301 generic and 83 brand-name prescriptions · $1,095,878 in drug cost · 54 antibiotic prescriptions to 19 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Rezurock18$489,279$27,182
Jakafi18$324,864$18,048
Cresemba34$200,312$5,892
Atovaquone12$4,624$385
Acyclovir50$1,182$24
See all 11 drugs
Every Part D drug this clinician prescribed
Rezurock18$489,279$27,182
Jakafi18$324,864$18,048
Cresemba34$200,312$5,892
Atovaquone12$4,624$385
Acyclovir50$1,182$24
Dexamethasone14$1,101$79
Tacrolimus21$756$36
Sulfamethoxazole-Trimethoprim36$236$7
Entecavir11$209$19
Prednisone21$172$8
Gabapentin12$146$12

Year by year

Part D prescribing by year
202438442None22%$1,095,878
2023183310% (0)21%$477,557
202255451None16%$1,086,542
2021493450% (0)12%$442,114
202038832None7%$269,531
201945142None17%$314,369
201836737NoneNone$173,694
2017328320% (0)9%$111,232
201630134None6%$71,416
201524732None11%$110,277
201414620None12%$30,250
201313NoneNoneNone$1,097

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 5 drugs

Part D drugs prescribed in 2023
Jakafi18$297,201$16,511
Acyclovir52$2,188$42
Tacrolimus21$971$46
Prednisone14$226$16
Sulfamethoxazole-Trimethoprim14$159$11

2022: 11 drugs

Part D drugs prescribed in 2022
Jakafi33$534,779$16,205
Posaconazole16$46,366$2,898
Acyclovir184$5,291$29
Dexamethasone26$2,779$107
Tacrolimus23$1,299$56
Prednisone16$256$16
Sulfamethoxazole-Trimethoprim30$225$8
Pantoprazole14$222$16
Prochlorperazine Maleate11$216$20
Ondansetron16$202$13
Levofloxacin11$133$12

2021: 15 drugs

Part D drugs prescribed in 2021
Jakafi17$290,849$17,109
Zarxio17$27,948$1,644
Eliquis11$5,785$526
Acyclovir138$3,895$28
Ursodiol28$2,890$103
Tacrolimus25$2,560$102
Mycophenolate Mofetil11$1,760$160
Dexamethasone15$1,061$71
Fluconazole17$764$45
Prochlorperazine Maleate19$339$18
Sulfamethoxazole-Trimethoprim32$245$8
Ondansetron21$241$11
Levofloxacin15$160$11
Prednisone12$153$13
Lorazepam21$116$6

2020: 9 drugs

Part D drugs prescribed in 2020
Posaconazole12$61,035$5,086
Tacrolimus50$3,100$62
Ursodiol13$2,231$172
Acyclovir91$2,131$23
Dexamethasone22$1,635$74
Fluconazole16$888$56
Prednisone20$301$15
Sulfamethoxazole-Trimethoprim42$279$7
Amlodipine Besylate14$57$4

2019: 12 drugs

Part D drugs prescribed in 2019
Noxafil24$132,374$5,516
Jakafi12$38,166$3,181
Atovaquone17$15,306$900
Tacrolimus37$4,626$125
Entecavir21$3,324$158
Acyclovir112$2,532$23
Dexamethasone11$620$56
Prednisone25$312$12
Sulfamethoxazole-Trimethoprim25$126$5
Famotidine13$120$9
Ondansetron11$88$8
Amlodipine Besylate15$28$2

2018: 11 drugs

Part D drugs prescribed in 2018
Noxafil13$77,463$5,959
Jakafi14$36,320$2,594
Entecavir25$10,387$415
Tacrolimus27$1,331$49
Acyclovir57$1,030$18
Famotidine24$237$10
Levofloxacin13$188$14
Ondansetron13$151$12
Sulfamethoxazole-Trimethoprim19$150$8
Ranitidine14$138$10
Amlodipine Besylate13$43$3

2017: 8 drugs

Part D drugs prescribed in 2017
Entecavir18$11,973$665
Tacrolimus26$1,022$39
Acyclovir57$769$13
Valacyclovir11$753$68
Prednisone22$351$16
Gabapentin13$138$11
Famotidine21$85$4
Sulfamethoxazole-Trimethoprim19$75$4

2016: 7 drugs

Part D drugs prescribed in 2016
Valacyclovir14$1,156$83
Acyclovir36$666$19
Ondansetron13$211$16
Ciprofloxacin11$164$15
Prednisone17$112$7
Sulfamethoxazole-Trimethoprim11$89$8
Famotidine16$66$4

2015: 6 drugs

Part D drugs prescribed in 2015
Tacrolimus14$1,511$108
Acyclovir34$769$23
Ondansetron11$353$32
Ciprofloxacin15$269$18
Lorazepam17$121$7
Famotidine13$90$7

2014: 1 drug

Part D drugs prescribed in 2014
Acyclovir18$413$23

Money from drug and device companies

$15 in 2023

A payment is not proof that care is biased.

Payments by company
Abbott LaboratoriesProclaim$15
1 payment
  • Meals for Proclaim · 2023-09-01 · $15
See the published payment
Every published payment
Abbott LaboratoriesMeals · 2023-09-01Proclaim$15

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Gamida Cell Inc. · Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies · 2024Their institution$34,006
Gamida Cell Inc. · Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies · 2025Their institution$14,552
Gamida Cell Inc. · Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies · 2023Their institution$9,696
Gamida Cell Inc. · Stem Cell Transplantation With Nicord (Omidubicel) Vs Standard Ucb in Patients With Leukemia, Lymphoma, and Mds · 2023Their institution$5,092

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1609983485
Licence
CA C128390, WA MD00043918California C128390: Current · expires 2027-05-31Washington MD.MD.00043918: Expired
Trained
Temple University School of Medicine, 2001 · 25 years ago
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Medical oncology (207RX0202X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2006-08-25
NPI last updated
2024-04-16
NPI record certified
2024-04-16

This is when the NPI record was last certified, not a medical board exam.